St. Jude Medical will buy portfolio company Spinal Modulation. The startup has submitted a PMA for its Axium Neurostimulator System to treat chronic pain. St. Jude will pay up to $175 million upfront with additional undisclosed payments upon FDA approval of the Axium system and with the achievement of undisclosed revenue targets.
Patterson Companies is said to be looking to shed its rehabilitation supply business in a deal that could reap the Minnesota-based medical device supplier up to $600 million, Reuters reported.
Those Mylan-Teva tie-up rumors just won't go away, and now, reports say the Israeli drugmaker is weighing a play for its generics rival. But make no mistake, Mylan said Friday: It wants to keep flying solo, and that includes wrapping up some M&A of its own.
Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.
Zimmer announced that the "outside date" for completing its merger with Biomet has been postponed from April 24, 2015, to July 23, 2015.
Actavis is trying to encourage an appeals court to let it force patients over to a new, patent-protected version of Alzheimer's treatment Namenda. Hundreds of millions in sales rest on the decision. But so far, the judges aren't offering any clues about their answer.
Serial acquirer Clinipace has bought up European CRO Accovion, striking its 6th deal in as many years as it seeks to expand its global reach.
Roche bought up a Stanford University-founded upstart with a promising approach to tracking the spread of cancer, eyeing a new tool in its expansive oncology R&D efforts.
When Mylan offered to buy Perrigo for $205 per share last Wednesday, the brewing $29 billion bid was hailed as the giant generics deal Wall Street has been anticipating. But this deal has an animal health angle too: If Mylan pulls it off, the acquisition will mark its entry into the veterinary market.
More than a couple of analysts agree that there may be a company out there that's after Mylan--and that that could have prompted the company's $28.9 billion bid for Ireland's Perrigo. But now that Mylan's made its offer, could that spur other Perrigo offers, too?